Sun Pharma has initiated a proactive voluntary withdrawal of eleven ophthalmic products, including Depopred and Brinolar, from the Indian market. The company cited 'abundant precaution' but did not specify the reason for the withdrawal.
Sun Pharma Distributors Ltd initiated a precautionary withdrawal of several eye drop products, including Depopred2ML and Lotepred-5ML, on July 17. The company cited patient safety as its highest priority, urging distributors to cease billing and return stocks. An expert highlighted the critical need for sterility and the risks of treatment interruption for patients.
The Indian market closed with modest gains on April 23, marking its third consecutive higher session, despite last-hour profit booking that erased most of the day's initial gains. The Sensex rose 0.12% and the Nifty gained 0.14%, driven by positive global cues and strong performance in broader markets.
Sun Pharma reports Q4FY26 results with a 22% YoY increase in net profit to Rs 2,714 crore, despite a 19% sequential drop in PAT and 6% decline in revenue from Q3FY26. Annual performance shows 12.9% YoY revenue growth to Rs 58,220 crore.
Sun Pharma, India's largest pharma company, has acquired US-listed Organon & Co for $11.8 billion (Rs 98,000 crore) in an all-cash transaction — the biggest-ever overseas pharma deal by an Indian company. Sun Pharma will pay $14 per share, a 24% premium to Organon's closing price. The acquisition adds over 140 high-growth markets including China, and portfolio of women's health, biosimilars, and legacy brands. Once completed, it will double Sun Pharma's revenue to $12.4 billion and EBITDA to $3.7 billion, ranking it among top 25 global pharmaceutical companies.
Sun Pharma has acquired Organon & Co for $11.75 billion, a deal designed to enhance its global commercial reach and diversify its portfolio into women's health and biosimilars, despite concerns regarding increased debt and integration challenges.
Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co for $11.75 billion in an all-cash deal. The acquisition values Organon at $14 per share and will help lift the Indian generics major into the top 25 global pharmaceutical companies with combined revenue of $12.4 billion. Organon, spun off from Merck in 2021, specializes in women's health and biosimilars with over 70 products sold across 140 countries. The deal will increase Sun Pharma's innovative medicine segment contribution from 20% to 27% of total sales.
Indian pharmaceutical giant Sun Pharma is set to acquire US-based Organon & Co. for $11.75 billion in an all-cash deal. This landmark acquisition, one of India's largest overseas ventures, will propel Sun Pharma into the top 25 global pharma companies. The move significantly bolsters its presence in women's health and biosimilars, expanding its global reach across 150 countries.
To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion.
Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co for $11.75 billion in an all-cash deal. The Indian drugmaker will pay $14 per share for all outstanding Organon shares, which was spun off from Merck in 2021. The acquisition will create a pharmaceutical giant with $12.4 billion in revenue, lifting Sun Pharma into the top 25 global pharmaceutical companies. Organon specializes in women's health and biosimilars with over 70 products sold across 140 countries.
To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion.
